Biosimilars in ophthalmology: “Is there a big change on the horizon?”

Ashish Sharma,1 Prahalad Reddy,1 Baruch D Kuppermann,2 Bandello Francesco,3 Anat Lowenstein41Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India; 2Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, CA, USA; 3Department...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sharma A, Reddy P, Kuppermann BD, Bandello F, Loewenstein A
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://doaj.org/article/676b3cc895384c879856be8c32b38788
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:676b3cc895384c879856be8c32b38788
record_format dspace
spelling oai:doaj.org-article:676b3cc895384c879856be8c32b387882021-12-02T02:21:30ZBiosimilars in ophthalmology: “Is there a big change on the horizon?”1177-5483https://doaj.org/article/676b3cc895384c879856be8c32b387882018-10-01T00:00:00Zhttps://www.dovepress.com/biosimilars-in-ophthalmology-is-there-a-big-change-on-the-horizon-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Ashish Sharma,1 Prahalad Reddy,1 Baruch D Kuppermann,2 Bandello Francesco,3 Anat Lowenstein41Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India; 2Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, CA, USA; 3Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milano, Italy; 4Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Abstract: Retinal disease management has witnessed remarkable advances in posterior segment pharmacotherapy with the development of anti-VEGF molecules such as Lucentis® (ranibizumab), Eylea® (aflibercept), and off-label bevacizumab (Avastin). The US patents for ranibizumab and aflibercept will expire in 2020 (though Regeneron has indicated that it might attempt to extend its US patent to June 2023 with additional patent claims), and their European patents will expire in 2022 and 2025. Aflibercept comes off patent in 2022 in People’s Republic of China and Japan. As soon as each patent expires, biosimilar molecules could potentially come in the mainstream clinical practice as a more cost-efficient choice in the form of generic biosimilars. It is difficult to predict how significant this shift would be in terms of more cost-effective clinical management and how it will impact the care in developed and developing world. It is important for clinicians to have a clear understanding about ophthalmic biosimilars before the industry brings these molecules to the mainstream clinical use globally.Keywords: biosimilar, Razumab®, Lucentis®, Eylea®, ophthalmologySharma AReddy PKuppermann BDBandello FLoewenstein ADove Medical Pressarticle- BiosimilarOphthalmologyLucentiaEyleaRazumabOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 2137-2143 (2018)
institution DOAJ
collection DOAJ
language EN
topic - Biosimilar
Ophthalmology
Lucentia
Eylea
Razumab
Ophthalmology
RE1-994
spellingShingle - Biosimilar
Ophthalmology
Lucentia
Eylea
Razumab
Ophthalmology
RE1-994
Sharma A
Reddy P
Kuppermann BD
Bandello F
Loewenstein A
Biosimilars in ophthalmology: “Is there a big change on the horizon?”
description Ashish Sharma,1 Prahalad Reddy,1 Baruch D Kuppermann,2 Bandello Francesco,3 Anat Lowenstein41Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India; 2Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, CA, USA; 3Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, Milano, Italy; 4Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Abstract: Retinal disease management has witnessed remarkable advances in posterior segment pharmacotherapy with the development of anti-VEGF molecules such as Lucentis® (ranibizumab), Eylea® (aflibercept), and off-label bevacizumab (Avastin). The US patents for ranibizumab and aflibercept will expire in 2020 (though Regeneron has indicated that it might attempt to extend its US patent to June 2023 with additional patent claims), and their European patents will expire in 2022 and 2025. Aflibercept comes off patent in 2022 in People’s Republic of China and Japan. As soon as each patent expires, biosimilar molecules could potentially come in the mainstream clinical practice as a more cost-efficient choice in the form of generic biosimilars. It is difficult to predict how significant this shift would be in terms of more cost-effective clinical management and how it will impact the care in developed and developing world. It is important for clinicians to have a clear understanding about ophthalmic biosimilars before the industry brings these molecules to the mainstream clinical use globally.Keywords: biosimilar, Razumab®, Lucentis®, Eylea®, ophthalmology
format article
author Sharma A
Reddy P
Kuppermann BD
Bandello F
Loewenstein A
author_facet Sharma A
Reddy P
Kuppermann BD
Bandello F
Loewenstein A
author_sort Sharma A
title Biosimilars in ophthalmology: “Is there a big change on the horizon?”
title_short Biosimilars in ophthalmology: “Is there a big change on the horizon?”
title_full Biosimilars in ophthalmology: “Is there a big change on the horizon?”
title_fullStr Biosimilars in ophthalmology: “Is there a big change on the horizon?”
title_full_unstemmed Biosimilars in ophthalmology: “Is there a big change on the horizon?”
title_sort biosimilars in ophthalmology: “is there a big change on the horizon?”
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/676b3cc895384c879856be8c32b38788
work_keys_str_mv AT sharmaa biosimilarsinophthalmologyldquoisthereabigchangeonthehorizonrdquo
AT reddyp biosimilarsinophthalmologyldquoisthereabigchangeonthehorizonrdquo
AT kuppermannbd biosimilarsinophthalmologyldquoisthereabigchangeonthehorizonrdquo
AT bandellof biosimilarsinophthalmologyldquoisthereabigchangeonthehorizonrdquo
AT loewensteina biosimilarsinophthalmologyldquoisthereabigchangeonthehorizonrdquo
_version_ 1718402531411886080